# US 2016/0250294 A1 · Composition-of-matter and method for treating cardiovascular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250294 A1
- Document ID: US20160250294A1
- Status: Published application
- Kind: A1
- Application number: 14/730,282
- Filed: 2015-06-04
- Published: 2016-09-01
- Earliest claimed: 2015-02-26
- Inventors: Jacob SCHNEIDERMAN
- Web page: https://patentgrep.com/patent/US20160250294A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 31/047: {Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/08: Materials for coatings
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 2300/43: Hormones, e.g. dexamethasone
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A composition-of-matter for treating cardiovascular disorders and a method of using same are provided The composition-of-matter includes a leptin antagonist and a carrier configured for localized release of the leptin antagonist.

## Claims

### Claim 1

A composition-of-matter for treating cardiovascular disorders comprising a leptin antagonist and a carrier configured for localized release of said leptin antagonist.

### Claim 2 (depends on 1)

The composition-of-matter of claim 1, wherein said carrier is a biodegradable support.

### Claim 3 (depends on 1)

The composition-of-matter of claim 1, wherein said biodegradable support is composed of poly glycolic and/or poly lactic acid.

### Claim 4 (depends on 1)

The composition-of-matter of claim 1, wherein said carrier is a hydrogel.

### Claim 5 (depends on 1)

The composition-of-matter of claim 1, wherein said carrier is configured as a film.

### Claim 6 (depends on 1)

The composition-of-matter of claim 1, wherein said carrier is device selected from the group consisting of a mesh, a balloon, a vascular graft.

### Claim 7 (depends on 1)

The composition-of-matter of claim 1, wherein said leptin antagonist is capable of binding a leptin receptor.

### Claim 8 (depends on 7)

The composition-of-matter of claim 7, wherein said leptin antagonist is incapable of dimerization.

### Claim 9 (depends on 8)

The composition-of-matter of claim 8, wherein said leptin antagonist is a modified leptin polypeptide.

### Claim 10 (depends on 1)

The composition-of-matter of claim 1, wherein said carrier is a depot-forming injectable composition.

### Claim 11

A method of treating a cardiovascular disorder comprising down-regulating an expression or activity of leptin by a carrier configured for localized release of leptin-antagonist in a cardiovascular tissue thereby treating the cardiovascular disorder locally.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The method of claim 11, wherein said cardiovascular tissue is aortic and/or mitral heart valve leaflet tissue.

### Claim 14 (depends on 11)

The method of claim 11, wherein said cardiovascular tissue is an outer wall or the inner (luminal surface) of an aorta.

### Claim 15 (depends on 11)

The method of claim 11, wherein said cardiovascular tissue is arterial or venous wall tissue.

### Claim 16 (depends on 11)

The method of claim 11, wherein said cardiovascular disorder is a vascular aneurysm.

### Claim 17 (depends on 11)

The method of claim 11, wherein said cardiovascular disorder is an aortic vascular disorder.

### Claim 18 (depends on 11)

The method of claim 11, wherein said localized release is effected via an intravascular catheter.

### Claim 19 (depends on 11)

The method of claim 11, wherein said cardiovascular disorder is left ventricular remodeling.

### Claim 20 (depends on 11)

The method of claim 11, wherein said local administration is effected via direct injection.

### Claim 21 (depends on 11)

The method of claim 11, wherein said carrier is a scaffold.

### Claim 22 (depends on 21)

The method of claim 21, wherein said scaffold is biodegradable.
